IDH1 and acute myeloid leukemia: A longer, 10-day DEC + VEN combination also proved to be an active salvage and bridging therapy in molecularly predefined R/R AML subpopulations, particularly in the case of NPM1, IDH1, IDH2, and FLT3-mutations [22].